Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2020-09-18, Stock:NVS, The news for the past five days is as follows:
2020-09-11: NEWS1: Analyst Report: Novartis AG.NEWS2: Where COVID-19 vaccines stand following AstraZeneca setback.NEWS3: Novartis Stock Should Rise 20%, Analyst Says.NEWS4: Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS).NEWS5: Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis.
2020-09-14: NEWS1: Novartis Reports Positive Data on Beovu for DME Indication.NEWS2: European Medicines Agency Approves Safety Label Update For Novartis' Beovu - Quick Facts .NEWS3: European Medicines Agency (EMA) approves safety label update for Novartis Beovu®.NEWS4: Novartis aims to expand Beovu use after safety fears hurt launch.NEWS5: Novartis says Beovu matched rival Eylea in visual acuity in eye disease.NEWS6: Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME).
2020-09-15: NEWS1: Novartis' Eye Drug's Safety Label Update Approved by EMA.NEWS2: Better Buy: Veeva Systems vs. Hubspot.NEWS3: Excited About AstraZeneca's Coronavirus Vaccine, Are Investors Immune to the Bigger Picture?.
2020-09-16: NEWS1: Novartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM.NEWS2: Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US.NEWS3: Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond.NEWS4: Technical Assessment: Bullish in the Intermediate-Term.
2020-09-17: NEWS1: BioNTech Buys a Plant to Manufacture Its Coronavirus Vaccine.NEWS2: Top Stock Reports for Novartis, Zoom Video & Caterpillar.NEWS3: Coronavirus update: Vaccine makers ramp up manufacturing as Trump stirs debate; NYC to delay school reopen.NEWS4: BioNTech To Buy Novartis' GMP German Manufacturing Site For COVID-19 Vaccine Production .

Answer: Decrease